Browsing: CELMoDs

In a Frontline Forum post-program interview, CancerNetwork spoke with Paul G. Richardson, MD, and Muhamed Baljevic, MD, FACP, about cereblon…

Muhamed Baljevic, MD, FACP, and Paul Richardson, MD, address how cereblon E3 ligase modulators (CELMoDs) such as mezigdomide and iberdomide…

Muhamed Baljevic, MD, FACP, associate professor of medicine and Director of Plasma Cell Disorders Research at Vanderbilt-Ingram Cancer Center, and…

Paul Richardson, MD, and Muhamed Baljevic, MD, FACP, explained why CELMoDs such as mezigdomide pair more synergistically with proteasome inhibitors,…

Expert consensus highlights a critical need to refine treatment sequencing for relapsed/refractory multiple myeloma, particularly as the field transitions toward…

In a conversation with CancerNetwork®, Sagar Lonial, MD, FACP, FASCO, discussed the potential implications of the FDA approving iberdomide plus…